Marcus Jonathan Coffey

In vivo aspirin supplementation inhibits nitric oxide consumption by human platelets (2005)

Williams, Paula Claire, Coffey, Marcus Jonathan, Coles, Barbara, Sanchez, Stephanie, Morrow, Jason D., Cockcroft, John Ronald, ...

Antiplatelet therapies improve endothelial function in atherosclerosis, suggesting that platelets regulate vascular nitric oxide (NO) bioactivity in vivo. Herein, washed platelets consumed NO on...

Depletion of iNOS-derived nitric oxide by prostaglandin H synthase-2 in inflammation-activated J774.2 macrophages through lipohydroperoxidase turnover (2005)

Clark, Stephen Robert, Anning, Peter Brian, Coffey, Marcus Jonathan, Roberts, Andrew Glyn, Marnett, Lawrence J., O'Donnell, Valerie Bridget

PGHS-2 (prostaglandin H synthase-2) is induced in mammalian cells by pro-inflammatory cytokines in tandem with iNOS [high-output ('inducible') nitric oxide synthase], and is co-localized with iNOS...

Interactions of 12-lipoxygenase with phospholipase A2 isoforms following platelet activation through the glycoprotein VI collagen receptor (2004)

Coffey, Marcus Jonathan, Coles, Barbara, Locke, Matthew, Bermudez-Fajardo, Alexandra, Williams, Paula Claire, Jarvis, Gavin E., ...

Recent studies implicate the collagen receptor, glycoprotein VI (GPVI) in activation of platelet 12-lipoxygenase (p12-LOX). Herein, we show that GPVI-stimulated 12-hydro(peroxy)eicosatetraenoic acid...

Platelet 12-lipoxygenase activation via glycoprotein VI: involvement of multiple signaling pathways in agonist control of H(P)ETE synthesis (2004)

Coffey, Marcus Jonathan, Jarvis, Gavin E, Gibbins, Jonathan M., Coles, Barbara, Barrett, Natasha E., Wylie, Oliver R.E., ...

Lipoxygenases (LOX) contribute to vascular disease and inflammation through generation of bioactive lipids, including 12-hydro(pero)xyeicosatetraenoic acid (12-H(P)ETE). The physiological mechanisms...

Platelet 12-lipoxygenase activation via glycoprotein VI: involvement of multiple signaling pathways in agonist control of H(P)ETE synthesis (2004)

Coffey, Marcus Jonathan, Jarvis, Gavin E, Gibbins, Jonathan M., Coles, Barbara, Barrett, Natasha E., Wylie, Oliver R.E., ...

Lipoxygenases (LOX) contribute to vascular disease and inflammation through generation of bioactive lipids, including 12-hydro(pero)xyeicosatetraenoic acid (12-H(P)ETE). The physiological mechanisms...

Characterization of nitric oxide consumption pathways by normal, chronic granulomatous disease and myeloperoxidase-deficient human neutrophils (2002)

Clark, Stephen Robert, Coffey, Marcus Jonathan, McLean, Rhona Murray, Collins, Peter William, Lewis, Malcolm John, Cross, Andrew R., ...

The detailed mechanisms by which acutely activated leukocytes metabolize NO and regulate its bioactivity are unknown. Therefore, healthy, chronic granulomatous disease (CGD) or myeloperoxidase...

Catalytic consumption of nitric oxide by 12/15- lipoxygenase: inhibition of monocyte soluble guanylate cyclase activation (2001)

Coffey, Marcus Jonathan, Natarajan, Rama, Chumley, Philip H., Coles, Barbara, Thimmalapura, Pushpa-Rekha, Nowell, Mari Ann, ...

12/15-Lipoxygenase (LOX) activity is elevated in vascular diseases associated with impaired nitric oxide (( small middle dot)NO) bioactivity, such as hypertension and atherosclerosis. In this study,...